Skip to content
10-Q

Quarterly Report

THESEUS PHARMACEUTICALS, INC.

0001558370-22-016129

← back to feed
Filed
Nov 3, 2022 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2022 · Oct 28, 2022 38.71M sh
Current Liabilities Q3 2022 · Sep 30, 2022 $7.81M
Current Liabilities Q3 2022 · Dec 31, 2021 $3.68M
Total Liabilities Q3 2022 · Sep 30, 2022 $11.7M
Total Liabilities Q3 2022 · Dec 31, 2021 $4.5M
Total Assets Q3 2022 · Sep 30, 2022 $230.29M
Total Assets Q3 2022 · Dec 31, 2021 $250.93M
Cash And Equivalents Q3 2022 · Dec 31, 2021 $244.66M
Cash And Equivalents Q3 2022 · Sep 30, 2021 $90.4M
Shares Diluted Q3 2022 · Sep 30, 2021 1.43M sh
Shares Diluted Q3 2022 · Sep 30, 2021 997.95K sh
Operating Cash Flow Q3 2022 · Sep 30, 2021 −$17.28M
Stockholders Equity Q3 2022 · Sep 30, 2021 −$50.15M
Stockholders Equity Q3 2022 · Jun 30, 2021 −$44.07M
Stockholders Equity restated Q3 2022 · Mar 31, 2021 −$38.2M
Stockholders Equity Q3 2022 · Dec 31, 2020 −$34.27M
Eps Diluted Q3 2022 · Sep 30, 2021 −$5.16
Eps Diluted Q3 2022 · Sep 30, 2021 −$18.69
Eps Basic Q3 2022 · Sep 30, 2021 −$5.16
Eps Basic Q3 2022 · Sep 30, 2021 −$18.69
Sga Expense Q3 2022 · Sep 30, 2021 $2.38M
Sga Expense Q3 2022 · Sep 30, 2021 $5.37M
Rd Expense Q3 2022 · Sep 30, 2021 $5M
Rd Expense Q3 2022 · Sep 30, 2021 $13.31M
Net Income Q3 2022 · Sep 30, 2021 −$7.37M
Net Income Q3 2022 · Sep 30, 2021 −$18.65M
Net Income Q3 2022 · Jun 30, 2021 −$6.81M
Net Income Q3 2022 · Mar 31, 2021 −$4.47M
Operating Income Q3 2022 · Sep 30, 2021 −$7.37M
Operating Income Q3 2022 · Sep 30, 2021 −$18.68M